TORONTO, ON / ACCESSWIRE / November 26, 2014 / Allegiance Equity Corporation ("ANQ") (TSX VENTURE: ANQ.V) announces today that has applied for TSX Venture Exchange approval to consummate a private placement of up to 15,000,000 Units at price of $0.05 per Unit to raise up to $750,000 of new equity financing. It is anticipated that the proceeds of the financing will be used as general working capital and to further develop the ANQ business model. Each Unit is to be comprised of one (1) Common Share and one (1) Common Share Purchase Warrant, with each Warrant being exercisable for three (3) years from the closing of the proposed private placement at an exercise price of $0.05 in the first year and $0.10 thereafter until expiry. The private placement is non-brokered and no finder's fees are payable in association therewith. All securities issued pursuant to this private placement will be subject to a hold period that will extend a minimum of four (4) months subsequent to the closing of this proposed private placement. ANQ currently has outstanding 18,165,957 common shares. Assuming consummation of the full amount of this private placement, there will be an additional 15,000,000 common shares outstanding (being 33,165,957 common shares) and, on a fully-diluted basis and after giving effect to the exercise of all outstanding share purchase warrants and incentive stock options granted under ANQ's stock option plan, ANQ anticipates it would have 48,663,957 common shares outstanding. About ANQ ANQ is an Ontario corporation that developed unique standardized mass-market nutraceutical products for the treatment of common ailments where present pharmaceutical treatments and Over-the-Counter (OTC) products fail to meet the needs of patients. ANQ has targeted markets having clearly identified product deficiencies and dissatisfied consumers afflicted with a variety of medical conditions. ANQ obtains regulatory approval and patents for these unique compounds and formulations and may produce and distribute or license its products for royalty revenues. Through its recently acquired wholly-owned subsidiary, CGX Life Sciences Inc., ANQ manufactures and distributes high quality nutraceuticals to provide safe, alternative treatments or to assist in the prevention of specific medical conditions, contain active ingredients formulated from natural herbal and botanical components. CGX's principal brands are CinG-X(TM) and Relieva(TM). For further information please contact: Scott Boyes, President and CEO scott@cgxlifesciences.com (416) 223-6874 Cautionary Statement Regarding Forward-Looking Information This news release includes certain "forward-looking statements" under applicable Canadian securities legislation that are not historical facts. Forward-looking statements involve risks, uncertainties, and other factors that could cause actual results, performance, prospects, and opportunities to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements in this news release include, but are not limited to, the Transaction and ANQ's objectives and intentions. Forward-looking statements are necessarily based on a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties and other factors which may cause actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic and social uncertainties; litigation, legislative, environmental and other judicial, regulatory, political and competitive developments; delay or failure to receive board, shareholder or regulatory approvals; those additional risks set out in ANQ's public documents filed on SEDAR at www.sedar.com; and other matters discussed in this news release. Although ANQ believes that the assumptions and factors used in preparing the forward-looking statements are reasonable, undue reliance should not be placed on these statements, which only apply as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Except where required by law, ANQ disclaims any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the Policies of the Exchange) accepts responsibility of the adequacy or accuracy of this release. SOURCE: Allegiance Equity Corporation